

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449/PTO</b>  <b>FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/584,837
				§ 371 Date	February 13, 2007
				First Named Inventor	Chikao MORIMO
				Art Unit	1635
Examiner Name	Chong, Kimberly				
Sheet	1	of	1	Attorney Docket Number	2144.0150002/RWE

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	US1	6,017,729	01-25-2000	Anderson <i>et al.</i>	
	US2				
	US3				
	US4				
	US5				
	US6				
	US7				
	US8				
	US9				
	US10				
	US11				
	US12				
	US13				
	US14				
	US15				
	US16				
	US17				
	US18				
	US19				
	US20				

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				
	FP1					
	FP2					
	FP3					
	FP4					
	FP5					
	FP6					
	FP7					
	FP8					
	FP9					

799486\_1.DOC

Examiner Signature	Date Considered
-----------------------	--------------------


\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)				Application Number	10/584,837
				§ 371 Date	February 13, 2007
				First Named Inventor	Chikao MORIMOTO
				Art Unit	1635
				Examiner Name	Chong, Kimberly
Sheet	1	of	1	Attorney Docket Number	2144.0150002/RWE



NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	NPL26	BIOSIS, Accession No. PREV199192004874, Biosis abstract for Valle, A. <i>et al.</i> , <i>Int. Immunol.</i> 3:229-236, Oxford University Press (1991)	
	NPL27	BIOSIS, Accession No. PREV199799590112, Biosis abstract for Blazquez, M.V. <i>et al.</i> , <i>Protoplasma</i> 197:26-33, Springer-Verlag Wien (1997)	
	NPL28	BIOSIS, Accession No. PREV200300053191, Biosis abstract for Bozinovski, S. <i>et al.</i> , <i>J. Biol. Chem.</i> 277:42808-42814, The American Society for Biochemistry and Molecular Biology, Inc. (November 2002)	
	NPL29	Bosisio, D. <i>et al.</i> , "Stimulation of toll-like receptor 4 expression in human mononuclear phagocytes by interferon- $\gamma$ : a molecular basis for priming and synergism with bacterial lipopolysaccharide," <i>Blood</i> 99:3427-3431, The American Society of Hematology (May 2002)	
	NPL30	Burns, K. <i>et al.</i> , "Inhibition of Interleukin 1 Receptor/Toll-like Receptor Signaling through the Alternatively Spliced, Short Form of MyD88 Is Due to Its Failure to Recruit IRAK-4," <i>J. Exp. Med.</i> 197:263-268, The Rockefeller University Press (2003)	
	NPL31	Cao, Z. <i>et al.</i> , "IRAK: A Kinase Associated with the Interleukin-1 Receptor," <i>Sci.</i> 271:1128-1131, American Association for the Advancement of Science (1996)	
	NPL32	Cooke, E.-L. <i>et al.</i> , "Functional analysis of the interleukin-1-receptor-associated kinase (IRAK-1) in interleukin-1 $\beta$ -stimulated nuclear factor $\kappa$ B (NF- $\kappa$ B) pathway activation: IRAK-1 associates with the NF- $\kappa$ B essential modulator (NEMO) upon receptor stimulation," <i>Biochem. J.</i> 359:403-410, Portland Press on behalf of the Biochemical Society (2001)	
	NPL33	Hegen, M. <i>et al.</i> , "Cross-linking of CD26 by antibody induces tryosine phosphorylation and activation of mitogen-activated protein kinase," <i>Immunol.</i> 90:257-264, Blackwell Scientific Publications, Inc. (1997)	
	NPL34	MEDLINE Accession No. NLM11960013, Medline abstract for Li, S. <i>et al.</i> , <i>Proc. Nat'l Acad. Sci. USA</i> 99:5567-5572, National Academy of Sciences (April 2002)	

799498\_1.DOC

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.